Hillstream Biopharma (NASDAQ:CNTN – Get Free Report) and CNFinance (NYSE:CNF – Get Free Report) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.
Profitability
This table compares Hillstream Biopharma and CNFinance’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Hillstream Biopharma | N/A | -20.06% | -15.90% |
| CNFinance | N/A | N/A | N/A |
Valuation and Earnings
This table compares Hillstream Biopharma and CNFinance”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hillstream Biopharma | N/A | N/A | -$35.92 million | ($0.50) | -4.62 |
| CNFinance | $80.76 million | 0.19 | -$65.43 million | $2.20 | 1.00 |
Hillstream Biopharma has higher earnings, but lower revenue than CNFinance. Hillstream Biopharma is trading at a lower price-to-earnings ratio than CNFinance, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Hillstream Biopharma and CNFinance, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hillstream Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| CNFinance | 1 | 1 | 0 | 1 | 2.33 |
Institutional & Insider Ownership
1.2% of Hillstream Biopharma shares are owned by institutional investors. 3.3% of Hillstream Biopharma shares are owned by insiders. Comparatively, 25.8% of CNFinance shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Hillstream Biopharma has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, CNFinance has a beta of -0.15, suggesting that its share price is 115% less volatile than the S&P 500.
Summary
CNFinance beats Hillstream Biopharma on 8 of the 11 factors compared between the two stocks.
About Hillstream Biopharma
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.
About CNFinance
CNFinance Holdings Limited, through its subsidiaries, provides home equity loan services in the People's Republic of China. It offers micro credit loan services for micro and small-enterprise owners; and loan lending agency services for financial institutions. The company provides bridge loan products, which are unsecured short-term loans to pay off borrowers' existing loans secured by real property. It operates approximately 87 branches and sub-branches in China. The company was founded in 1999 and is headquartered in Guangzhou, the People's Republic of China.
Receive News & Ratings for Hillstream Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hillstream Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
